Active Not Recruiting PHASE1 INTERVENTIONAL 2-arm NCT04340596

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Sponsor: ImmunityBio, Inc.

Conditions HIV Infection

Interventions 10-1074 N-803 (IL-15 Superagonist) VRC07-523LS

Updated 19 times since 2020 Last updated: Mar 24, 2025 Started: May 21, 2021 Primary completion: Jun 30, 2026 Completion: Dec 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on HIV Infection, this trial is ongoing. The trial is conducted by ImmunityBio, Inc. and has accumulated 19 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

19 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE1
Apr 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Feb 2025 — Apr 2025 [monthly]

Recruiting PHASE1
Nov 2024 — Feb 2025 [monthly]

Recruiting PHASE1
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE1

▶ Show 14 earlier versions

Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1
Oct 2023 — Apr 2024 [monthly]

Recruiting PHASE1
Sep 2022 — Oct 2023 [monthly]

Recruiting PHASE1
May 2022 — Sep 2022 [monthly]

Recruiting PHASE1
Feb 2022 — May 2022 [monthly]

Recruiting PHASE1
Dec 2021 — Feb 2022 [monthly]

Recruiting PHASE1
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE1
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE1
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Sep 2021 [monthly]

Not Yet Recruiting PHASE1
May 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ImmunityBio, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)
Rockefeller University

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birmingham, United States , Boston, United States , Chapel Hill, United States , Chicago, United States , Cleveland, United States , Los Angeles, United States , New York, United States , Newark, United States , Philadelphia, United States , San Diego, United States and 3 more locations